Treatment of benign chronic gastric ulcer with ranitidine: A randomized, double-blind, and placebo-controlled six week trial

Basil I. Hirschowitz, Vincent DeLuca, David Graham, Stanley Lorber, Peter Bright-Asare, Ronald Katon

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

A randomized, multicenter, double-blind, placebo-controlled study was conducted to determine whether ranitidine 150 mg b.i.d. for 6 weeks would expedite endoscopic healing or relief of symptoms in patients with benign gastric ulcer. Of 203 patients enrolled, 101 received ranitidine and 102 received placebo. Endoscopic evaluations were conducted at baseline and at 2 and 6 weeks. At 6 weeks 68% of the patients treated with ranitidine had healed compared with 53% in the placebo group (p = 0.02). In those patients who had not healed by 6 weeks, ranitidine provided greater relief from pain than placebo. More patients in the placebo group dropped out of the study because of worsening symptoms (13 versus 4, p = 0.04). No differences in laboratory abnormalities or incidence of adverse events were detected between the two study groups. These results indicate that ranitidine 150 mg b.i.d. is superior to placebo in the treatment of benign gastric ulcer.

Original languageEnglish (US)
Pages (from-to)371-376
Number of pages6
JournalJournal of clinical gastroenterology
Volume8
Issue number3
DOIs
StatePublished - Jun 1986

Keywords

  • Gastric ulcer
  • Histamine H-receptor antagonists
  • Ranitidine

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Treatment of benign chronic gastric ulcer with ranitidine: A randomized, double-blind, and placebo-controlled six week trial'. Together they form a unique fingerprint.

  • Cite this